Kocarek T A, Schuetz E G, Guzelian P S
Department of Medicine, Medical College of Virginia, Richmond 23298.
Toxicol Appl Pharmacol. 1993 Jun;120(2):298-307. doi: 10.1006/taap.1993.1115.
Lovastatin (LOVA) is a potent inhibitor of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase widely used in clinical practice. We treated primary cultures of adult rat hepatocytes, maintained in a minimal, serum-free medium on Matrigel, a reconstituted basement membrane, with this drug, and found that the amounts of P450 2B2 mRNA detected on Northern blots were increased at the same doses (10(-5) to 3 x 10(-5) M) required for induction of HMG-CoA reductase mRNA, a gene known to be under oxysterol regulatory control. LOVA treatment produced selective effects increasing also the mRNA levels for P450s 2C6, 2C7, 3A1, and 4A1 but not for 1A1, 2A1/2, or NADPH-cytochrome P450 oxidoreductase. LOVA treatment increased the induction of 2B1/2 mRNA in cells cotreated with either phenobarbital (PB; 10(-4) M) or clotrimazole (CTZ; 10(-5) M), or of 3A1 mRNA in cells cotreated with PB (2 x 10(-3) M), but not dexamethasone (10(-5) M. LOVA treatment did not potentiate the induction of 1A1 or 4A1 mRNA in cells cotreated with beta-naphthoflavone (10(-5) M) or ciprofibrate (10(-4) M), respectively. In contrast to the potentiation of 2B1/2 mRNA induction produced by treatments with LOVA in combination with PB or CTZ, cotreatment of hepatocytes with PB and CTZ did not result in increased induction relative to that seen in cells treated with either agent alone. Treatment of hepatocyte cultures with either mevalonate (3 x 10(-4) to 3 x 10(-3) M), the immediate product of HMG-CoA reductase, or 25-hydroxycholesterol (10(-6) to 10(-5) M), a model oxysterol, resulted in dose-dependent suppression of 2B1/2 mRNA induction in cells treated with PB-like inducers. Taken together, our results demonstrate that LOVA is a unique inducer of P450 mRNA in cultured rat hepatocytes and implicate oxysterols as potential intracellular modulators of 2B1/2 induction. We conclude that endogenous metabolic factors including those related to cholesterol biosynthesis are critical in induction of liver cytochromes P450 2B1 and 2B2 by PB and "PB-like" agents.
洛伐他汀(LOVA)是一种强效的3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂,在临床实践中广泛应用。我们用这种药物处理了原代培养的成年大鼠肝细胞,这些细胞在基质胶(一种重组基底膜)上的最低限度无血清培养基中培养,发现Northern印迹检测到的P450 2B2 mRNA量在诱导HMG-CoA还原酶mRNA所需的相同剂量(10^(-5)至3×10^(-5) M)下增加,HMG-CoA还原酶基因已知受氧化甾醇调控。LOVA处理产生了选择性作用,还增加了P450s 2C6、2C7、3A1和4A1的mRNA水平,但对1A1、2A1/2或NADPH-细胞色素P450氧化还原酶没有影响。LOVA处理增加了与苯巴比妥(PB;10^(-4) M)或克霉唑(CTZ;10^(-5) M)共同处理的细胞中2B1/2 mRNA的诱导,或与PB(2×10^(-3) M)共同处理的细胞中3A1 mRNA的诱导,但对地塞米松(10^(-5) M)没有影响。LOVA处理并没有增强与β-萘黄酮(10^(-5) M)或环丙贝特(10^(-4) M)分别共同处理的细胞中1A1或4A1 mRNA的诱导。与LOVA与PB或CTZ联合处理产生的2B1/2 mRNA诱导增强相反,肝细胞与PB和CTZ共同处理相对于单独用任何一种药物处理的细胞,诱导并没有增加。用HMG-CoA还原酶的直接产物甲羟戊酸(3×10^(-4)至3×10^(-3) M)或模型氧化甾醇25-羟基胆固醇(10^(-6)至10^(-5) M)处理肝细胞培养物,导致在用PB样诱导剂处理的细胞中2B1/2 mRNA诱导呈剂量依赖性抑制。综上所述,我们的结果表明,LOVA是培养的大鼠肝细胞中P450 mRNA的独特诱导剂,并暗示氧化甾醇是2B1/2诱导的潜在细胞内调节剂。我们得出结论,包括与胆固醇生物合成相关的那些在内的内源性代谢因子在PB和“PB样”药物诱导肝细胞色素P450 2B1和2B2中起关键作用。